3 Stocks I'll Never Sell

If there's one thing I've learned over my 21 years as an investor, it's that high-quality businesses often increase in value over time. While recessions and inevitable stock market corrections will occasionally test investors' resolve, the fact is that good companies tend to make investors money, if they're patient -- the key word being "patient." As for me, of the more than one dozen holdings currently in my portfolio, there are three that I have absolutely no intention of ever selling. Though business dynamics are constantly evolving around these three companies, they have all the tools necessary to continue thriving.

First up is bank stock Bank of America (NYSE:BAC), which I bought into back in November 2011. Having an initial cost basis of $5.21 certainly adds to my desire to continue holding, but it's so much more than just a low cost-basis. Cancer-drug developer Exelixis (NASDAQ:EXEL) is another company that I have absolutely no intention of ever selling. Although I've held a position in Exelixis since March 2014 and have an exceptionally low cost-basis, there's plenty to like about where Exelixis is headed. Finally, I don't foresee myself ever getting rid of my position in telecom and content behemoth AT&T (NYSE:T), which was initiated in December 2018.

Source: Motley Fool

Related Articles:
- The Most Important Thing To Consider When Selecting A Dividend Stock
- 5 Healthcare Stocks With Growing Dividends Yielding In Excess of 2%
- 3 Powerful Concepts for Compounding Wealth with Dividend Stocks
- Why We Are Dividend Growth Investors
- 3 Higher Yielding, Lower Risk Stocks To Perk Up Your Dividend Income